WS #15559
The FDA has approved atezolizumab in combination with chemotherapy for the adjuvant treatment of stage III dMMR colon cancer, marking a significant advancement in oncology care. Additionally, BTIG has raised its price target for Haemonetics to $130, maintaining a Buy rating. These developments provide niche positive catalysts for the healthcare sector, particularly for oncology and medical device companies, though they are overshadowed by the broader market's tech-focused selloff.
Healthcare and Biotech Developments
The FDA has approved atezolizumab in combination with chemotherapy for the adjuvant treatment of stage III dMMR colon cancer, marking a significant advancement in oncology care. Additionally, BTIG has raised its price target for Haemonetics to $130, maintaining a Buy rating. These developments provide niche positive catalysts for the healthcare sector, particularly for oncology and medical device companies, though they are overshadowed by the broader market's tech-focused selloff.